与努力相关的动机功能障碍的潜在治疗方法:评估新型非典型多巴胺转运抑制剂
Alev Ecevitoglu1, Nicolette Meka1, Renee A Rotolo1
1Psychological Sciences, University of Connecticut, Storrs, CT, 06269-1020, USA.
概括
新型多巴胺转运体 (DAT) 抑制剂,特别是JJC8-088,JJC8-089和RDS3-094,在老鼠模型中有效逆转了与努力相关的动机功能障碍. 这些发现表明,对于抑郁症等疾病的潜在新疗法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 行为科学 行为科学
背景情况:
- 动机功能障碍,包括疲劳和精神障碍,是神经精神疾病 (如抑郁症) 的关键症状.
- 在临床前模型中,基于努力的选择任务有助于研究减少的动机和努力.
- 多巴胺转运体 (DAT) 抑制剂在逆转这些功能障碍方面表现有希望,但经典阻断剂有风险.
研究的目的:
- 描述具有不同神经化学特征的新型modafinil-analog DAT抑制剂的与劳动力相关的影响.
- 评估这些化合物的有效性,以逆转药理学诱导的动机缺陷使用既定的行为任务.
主要方法:
- 在Sprague-Dawley大鼠中使用了两种不同的基于努力的选择任务.
- 化合物JJC8-088,JJC8-089,RDS3-094和JJC8-091被测试了它们对基于努力的决策的影响.
- 使用VMAT-2抑制剂tetrabenazine诱导了动机功能障碍.
主要成果:
- JJC8-088,JJC8-089和RDS3-094成功地扭转了四贝纳诱导的低功耗偏差,增加了对高功耗任务的偏好.
- JJC8-089在雄性和雌性大鼠中都显示出有效性.
- JJC8-091没有产生类似的效果,可能是由于它对DAT的独特结合特征.
结论:
- 新型DAT抑制剂 (JJC8-088,JJC8-089,RDS3-094) 显示出治疗与努力相关的动机缺陷的潜力.
- 了解DAT抑制剂的神经化学特征对于确定有效的治疗候选者至关重要.
- 对各种DAT抑制剂的进一步研究可能会为人类的动机功能障碍提供治疗方法.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
229
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
229
01:24Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
315
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
315
01:25Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K